Adipose tissue is an energy storage organ but also has been more recognized as an important component of the endocrine system by regulating metabolism through the secretion of various hormone-like substances known as adipokines ([@B1]). Adiponectin is the adipokine with the highest plasma concentration and is associated with glucose and lipid homeostasis as well as insulin sensitivity ([@B1]--[@B3]). In humans, plasma adiponectin concentration was inversely correlated with body weight, body mass index (BMI), and insulin resistance in cross-sectional research ([@B2], [@B4]). On the other hand, weight reduction through calorie-restricted diet or bariatric surgery was associated with an increase in plasma adiponectin ([@B5], [@B6]). This finding suggests that plasma adiponectin concentration is a consequence of body fat mass. In animal research, however, administration of adiponectin resulted in weight loss and increased fatty acid oxidation in muscle in high-fat/sucrose diet fed mice ([@B7]). These animal findings suggest that adiponectin may be involved in energy homeostasis and have weight-regulating functions. However, the causal relationship of plasma adiponectin with body weight in humans is not clear from existing cross-sectional observational research. A few prospective human studies have investigated the association between adiponectin concentration and body weight, but were inconclusive ([@B8]--[@B11]). Low adiponectin concentration was not associated with the development of obesity in Pima Indians, elderly Caucasians, or Afro-Jamaicans ([@B8]--[@B10]). However, higher adiponectin concentrations were associated with greater weight gain in healthy women in the Nurses' Health Study ([@B11]).

As for the relationship between adiponectin and specific fat depots, controversy exists from previous cross-sectional studies on whether abdominal visceral fat or abdominal subcutaneous fat is more closely associated with plasma adiponectin concentration. Several studies have shown that abdominal visceral fat is inversely associated with adiponectin concentration ([@B2], [@B12], [@B13]), but other studies reported that abdominal subcutaneous fat rather than abdominal visceral fat correlated inversely with adiponectin ([@B14], [@B15]). On the contrary, lower extremity fat depots were positively associated with adiponectin ([@B14], [@B16]). To our knowledge, there is no prospective research on the association of adiponectin concentration with future body composition directly measured by computed tomography (CT).

Likewise, although insulin-sensitizing effects of adiponectin are well established in rodent models ([@B17], [@B18]), it remains unclear whether adiponectin causes changes in insulin sensitivity in humans ([@B19]). Reverse causation has also been postulated because the inverse association between adiponectin and insulin resistance may reflect suppression of adiponectin production by compensatory hyperinsulinemia ([@B19]), but this can be addressed by prospective research.

Therefore, the purpose of the current study was to investigate the association of baseline plasma concentration of adiponectin with future regional body fat distribution and BMI over a 5-year follow-up in a Japanese American cohort of men and women. We also examined whether adiponectin concentration can predict future insulin sensitivity independent of directly measured fat depots in this population.

Subjects and Methods {#s8}
====================

Study population {#s9}
----------------

The study population consisted of third-generation (Sansei) Japanese Americans of 100% Japanese ancestry enrolled in the Japanese-American Community Diabetes Study. Methods for selection and recruitment of participants have been described previously ([@B20]). The Japanese-American Community Diabetes Study population is representative of Japanese American residents of King County, WA, which includes the Seattle-Tacoma-Bellevue metropolitan statistical area. For the current analysis, eligible subjects had a fasting plasma glucose \<126 mg/dL, a 2-hour plasma glucose after a 75-g oral glucose tolerance test \<200 mg/dL, and were not taking glucose-lowering agents (n = 253). The study received approval from the University of Washington Human Subjects Division and all subjects provided written informed consent (institutional review board number: 34469).

Clinical and laboratory examination {#s10}
-----------------------------------

Blood samples were obtained after an overnight fast of 10 hours. A 75-g oral glucose tolerance test was used to define prediabetes and diabetes mellitus using American Diabetes Association criteria ([@B21]). Diabetes was defined as fasting plasma glucose ≥126 mg/dL, 2-hour postload plasma glucose ≥200 mg/dL, or current treatment with oral antidiabetes drugs or insulin. Prediabetes was defined as diagnosed as fasting plasma glucose from 100 to 125 mg/dL or 2-hour plasma glucose levels between 140 and 199 mg/dL and no diagnosis of diabetes.

Plasma glucose was measured by the hexokinase method using an autoanalyzer (Department of Laboratory Medicine, University of Washington, Seattle, WA). Plasma insulin was measured by radioimmunoassay (Diabetes Research Center, University of Washington). Updated computer models for homeostasis model assessment 2 (HOMA2) were used to calculate the indices of insulin resistance (HOMA2-IR) and insulin secretion (HOMA2%B) (<https://www.dtu.ox.ac.uk/homacalculator/>) ([@B22]).

Plasma total adiponectin concentrations were determined in duplicate using a commercially available radioimmunoassay kit (Linco Research, St. Charles, MO). Intra-assay and interassay coefficients of variation were \<6.21% and \<9.25%, respectively. Plasma was stored at −70°C until assays were performed.

BMI was computed as weight in kilograms divided by height in meters squared (kg/m^2^). Single (1-cm) CT scan slices of the thorax on inspiration at the level of the nipples, the abdomen at the level of the umbilicus, and the midthigh at a level halfway between the greater trochanter and the superior margin of the patella were analyzed for cross-sectional area of adipose tissue (centimeters squared), defined as ranging from −250 to −50 Hounsfield units using density contour software (standard GE 8800, Milwaukee, WI) ([@B23]). In addition to subcutaneous fat at each of these sites, abdominal visceral adiposity was measured as intra-abdominal fat area within the transversalis fascia in centimeters squared at the level of the umbilicus. Total fat area was calculated as the sum of intra-abdominal fat area and subcutaneous abdominal fat area, thorax subcutaneous fat area, and twice the left thigh subcutaneous fat area. Total subcutaneous fat area was defined as total fat area minus the intra-abdominal fat area.

Statistical analysis {#s11}
--------------------

Continuous variables are expressed as means ± standard deviation and categorical variables expressed as numerals. Continuous variable distributions were assessed for skewness, and, when found in the case of fasting insulin, HOMA2-IR, and HOMA2%B, were logarithmically transformed for all analyses. An independent *t* test was used to compare differences between means. Within-person change from baseline to 5-year follow-up measurements was analyzed by paired *t* tests. We estimated unadjusted Pearson correlation coefficients between baseline plasma adiponectin and metabolic variables, anthropometric variables, or body composition measures at 5 years; we also performed these analyses while adjusting for the baseline level of the dependent variables to estimate associations with change over 5 years as reflected by the partial correlation coefficients. Multiple linear regression analysis was used to determine independent associations between BMI, regional fat depots, and insulin resistance at 5 years in relation to baseline plasma adiponectin concentrations. The presence of multicollinearity in multivariate models was evaluated using the variance inflation factor, with a value \>5 suggesting its presence ([@B24]). The data were analyzed using IBM Statistical Package for the Social Sciences Statistics for Windows, version 22.0 (IBM Corp., Armonk, NY). A two-sided *P* value \<0.05 was considered to indicate statistical significance.

Results {#s12}
=======

Of the 253 nondiabetic participants, we excluded 35 subjects with missing CT adiposity data at baseline or 5-year follow-up. The clinical and laboratory characteristics of the subjects are summarized in [Table 1](#T1){ref-type="table"}. There were 218 subjects included in this study with mean age of 51.7 ± 10.1 years, mean BMI 24.7 ± 3.6 kg/m^2^, and 36.2% men. Adiponectin concentrations were significantly higher for women than men. Over the 5-year follow-up period, there were statistically significant changes in weight and BMI.

###### 

**Clinical Characteristics of Study Subjects**

                                            Baseline                                           5-y Follow-Up                                                                                            
  ----------------------------------------- -------------------------------------------------- --------------- ---------------------------------------------------------------------------------------- --------------------------------------------------
  Age (y)                                   45.9 ± 3.5[*^a^*](#t1n1){ref-type="table-fn"}      55.0 ± 11.1     50.8 ± 3.9[*^a^*](#t1n1){ref-type="table-fn"}^,^[*^b^*](#t1n2){ref-type="table-fn"}      60.6 ± 11.1[*^b^*](#t1n2){ref-type="table-fn"}
  Weight (kg)                               73.7 ± 9.8[*^a^*](#t1n1){ref-type="table-fn"}      57.6 ± 9.6      75.4 ± 10.9[*^a^*](#t1n1){ref-type="table-fn"}^,^[*^b^*](#t1n2){ref-type="table-fn"}     58.6 ± 9.8[*^b^*](#t1n2){ref-type="table-fn"}
  BMI (kg/m^2^)                             25.7 ± 3.2[*^a^*](#t1n1){ref-type="table-fn"}      24.1 ± 3.8      26.3 ± 3.5[*^a^*](#t1n1){ref-type="table-fn"}^,^[*^b^*](#t1n2){ref-type="table-fn"}      24.6 ± 3.8[*^b^*](#t1n2){ref-type="table-fn"}
  Fasting plasma glucose (mg/dL)            100.1 ± 8.0[*^a^*](#t1n1){ref-type="table-fn"}     96.3 ± 9.0      96.5 ± 9.4[*^b^*](#t1n2){ref-type="table-fn"}                                            95.1 ± 11.3
  2-h plasma glucose (mg/dL)                131.6 ± 26.7[*^a^*](#t1n1){ref-type="table-fn"}    142.8 ± 27.9    134.0 ± 36.2[*^a^*](#t1n1){ref-type="table-fn"}                                          147.2 ± 34.6
  Fasting insulin (μU/mL)                   16.7 ± 14.1                                        14.3 ± 7.9      15.4 ± 9.8                                                                               14.5 ± 8.3
  HOMA2-IR                                  2.2 ± 1.7                                          1.9 ± 1.0       2.0 ± 1.2                                                                                1.9 ± 1.1
  HOMA2%B                                   127.0 ± 68.6                                       123.2 ± 38.1    128.4 ± 47.5                                                                             127.5 ± 41.8
  Adiponectin (μg/mL)                       7.3 ± 3.3[*^a^*](#t1n1){ref-type="table-fn"}       11.9 ± 4.7      ---                                                                                      ---
  Total fat area (cm^2^)                    417.0 ± 166.3[*^a^*](#t1n1){ref-type="table-fn"}   611.9 ± 246.9   455.7 ± 161.2[*^a^*](#t1n1){ref-type="table-fn"}^,^[*^b^*](#t1n2){ref-type="table-fn"}   635.1 ± 236.5
  Total subcutaneous fat area (cm^2^)       338.1 ± 139.6[*^a^*](#t1n1){ref-type="table-fn"}   538.0 ± 219.1   363.1 ± 134.4[*^a^*](#t1n1){ref-type="table-fn"}^,^[*^b^*](#t1n2){ref-type="table-fn"}   557.9 ± 211.2[*^b^*](#t1n2){ref-type="table-fn"}
  Abdominal visceral fat area (cm^2^)       78.9 ± 38.6                                        74.9 ± 39.8     91.7 ± 41.2[*^a^*](#t1n1){ref-type="table-fn"}^,^[*^b^*](#t1n2){ref-type="table-fn"}     77.0 ± 38.6
  Abdominal subcutaneous fat area (cm^2^)   154.5 ± 68.8[*^a^*](#t1n1){ref-type="table-fn"}    210.6 ± 98.6    169.2 ± 69.6[*^a^*](#t1n1){ref-type="table-fn"}^,^[*^b^*](#t1n2){ref-type="table-fn"}    219.0 ± 93.5
  Thigh subcutaneous fat area (cm^2^)       47.5 ± 18.9[*^a^*](#t1n1){ref-type="table-fn"}     93.8 ± 35.6     46.7 ± 18.3[*^a^*](#t1n1){ref-type="table-fn"}                                           89.7 ± 33.6
  NGT/prediabetes/diabetes (n)              31/48/0                                            48/91/0         37/35/7                                                                                  61/63/15

Data are presented as means ± standard deviation.

NGT, normal glucose tolerance.

P \< 0.05, significant difference between men and women.

P \< 0.05, significant difference between baseline examinations values and 5-y follow-up examination values.

The cross-sectional analysis of baseline measurements revealed that adiponectin concentration was negatively associated with fasting plasma glucose, fasting insulin, HOMA2-IR, HOMA2%B weight, BMI, abdominal visceral fat area, and abdominal subcutaneous fat area, and was positively associated with thigh subcutaneous fat area ([Table 2](#T2){ref-type="table"}).

###### 

**Correlations Between Baseline Plasma Adiponectin and Measures of Body Fat or Metabolic Characteristics at Baseline and 5-y Follow-Up**

  Cross-Sectional Analysis          Prospective Analysis                                                                           
  --------------------------------- ---------------------- --------- --------------------------------- -------- --------- -------- ---------
  Fasting plasma glucose            −0.233                 0.001     Fasting plasma glucose            −0.251   \<0.001   −0.134   0.048
  2-h plasma glucose                0.035                  0.603     2-h plasma glucose                −0.033   0.625     −0.072   0.289
  Fasting insulin                   −0.315                 \<0.001   Fasting insulin                   −0.340   \<0.001   −0.249   0.002
  HOMA2-IR                          −0.318                 \<0.001   HOMA2-IR                          −0.345   \<0.001   −0.250   \<0.001
  HOMA2%B                           −0.226                 0.001     HOMA2%B                           −0.219   0.001     −0.165   0.015
  Weight                            −0.525                 \<0.001   Weight                            −0.518   \<0.001   −0.068   0.316
  BMI                               −0.366                 \<0.001   BMI                               −0.363   \<0.001   −0.069   0.312
  Total fat area                    −0.085                 0.216     Total fat area                    −0.108   0.116     −0.044   0.524
  Total subcutaneous fat area       −0.045                 0.508     Total subcutaneous fat area       −0.053   0.441     0.001    0.983
  Abdominal visceral fat area       −0.273                 \<0.001   Abdominal visceral fat area       −0.324   \<0.001   −0.194   0.004
  Abdominal subcutaneous fat area   −0.137                 0.043     Abdominal subcutaneous fat area   −0.120   0.078     0.008    0.903
  Thigh subcutaneous fat area       0.164                  0.016     Thigh subcutaneous fat area       0.173    0.011     0.087    0.207

Results are expressed as correlation coefficients.

Partial correlation coefficients for variables at 5-y follow-up are adjusted for the baseline levels.

In prospective analysis, the patterns of association between baseline adiponectin concentration and 5-year values of parameters were similar to the cross-sectional analysis except for a nonsignificant correlation with abdominal subcutaneous fat area in unadjusted analysis, although the magnitude of the correlation coefficient was similar to the cross-sectional result ([Table 2](#T2){ref-type="table"}). We further analyzed 5-year levels while adjusting for baseline levels to permit estimation of the association between adiponectin concentration and change over 5 years. In these adjusted analyses, baseline adiponectin concentration was negatively associated with 5-year change in fasting plasma glucose, fasting insulin, HOMA2-IR, HOMA2%B, and abdominal visceral fat area at 5 years, but no important association was seen with weight, BMI, or thigh subcutaneous fat area.

We next performed multivariate analyses to determine whether baseline adiponectin concentration independently predicted 5-year BMI and abdominal visceral fat area. Baseline adiponectin concentration was not significantly associated with future BMI ([Table 3](#T3){ref-type="table"}). Age and baseline BMI were independent predictors of 5-year BMI. Baseline adiponectin concentration was significantly and inversely associated with 5-year abdominal visceral fat area after adjusting for baseline traits (including age, sex, BMI, HOMA2-IR, abdominal visceral fat area, abdominal subcutaneous fat area, thigh subcutaneous fat area) and 5-year weight change ([Table 4](#T4){ref-type="table"}). We examined the first-order interaction term between adiponectin and sex in the prediction of abdominal visceral fat area in model of [Table 4](#T4){ref-type="table"}, but found it to not be statistically significant (interaction term coefficient, 0.122; *P* = 0.620). In addition, no significant relationships between baseline adiponectin concentration and future abdominal or thigh subcutaneous fat area were observed when using the same covariates shown in model of [Table 4](#T4){ref-type="table"} (data not shown).

###### 

**Multivariate Linear Regression Analysis of the Prediction of BMI at 5-y Follow-Up**

                                    Model (*R*^2^ = 0.863)   
  --------------------------------- ------------------------ ---------
  Adiponectin                       −0.001                   0.989
  Age                               −0.074                   0.036
  Female sex                        −0.001                   0.981
  BMI                               0.905                    \<0.001
  Abdominal visceral fat area       −0.057                   0.161
  Abdominal subcutaneous fat area   0.020                    0.709
  Thigh subcutaneous fat area       0.024                    0.547
  HOMA2-IR                          0.049                    0.110

Model adjusted for baseline traits (age, sex, BMI, abdominal visceral fat area, abdominal subcutaneous fat area, thigh subcutaneous fat area, HOMA2-IR).

Data are expressed as standardized *β*.

###### 

**Multivariate Linear Regression Analysis of the Prediction of Abdominal Visceral Fat Area at 5-y Follow-Up**

                                    Model (*R*^2^ = 0.715)   
  --------------------------------- ------------------------ ---------
  Adiponectin                       −0.104                   0.037
  Age                               0.184                    \<0.001
  Female sex                        −0.066                   0.324
  BMI                               0.245                    0.004
  Weight change                     0.458                    \<0.001
  Abdominal visceral fat area       0.634                    \<0.001
  Abdominal subcutaneous fat area   −0.119                   0.123
  Thigh subcutaneous fat area       0.022                    0.705
  HOMA2-IR                          −0.020                   0.661

Model adjusted for baseline traits (age, sex, BMI, abdominal visceral fat area, abdominal subcutaneous fat area, thigh subcutaneous fat area, HOMA2-IR) and change in weight.

Data are expressed as standardized *β*.

As shown in [Table 5](#T5){ref-type="table"}, baseline adiponectin was significantly associated with greater 5-year HOMA2-IR after adjustment for baseline traits (age, sex, BMI, HOMA2-IR, abdominal visceral fat area, abdominal subcutaneous fat area, thigh subcutaneous fat area) and weight change. Female sex, BMI, weight change, and abdominal visceral fat area at baseline were also predictors of future HOMA2-IR. No significant interaction was seen between baseline adiponectin and 5-year HOMA2-IR by sex (interaction term coefficient, −0.243; *P* = 0.517) when this interaction term was inserted into the regression model in [Table 5](#T5){ref-type="table"}.

###### 

**Multivariate Linear Regression Analysis of the Prediction of HOMA2-IR at 5-y Follow-Up**

                                    Model (*R*^2^ = 0.390)   
  --------------------------------- ------------------------ ---------
  Adiponectin                       −0.223                   0.002
  Age                               −0.006                   0.937
  Female                            0.264                    0.008
  BMI                               0.258                    0.036
  Weight change                     0.295                    \<0.001
  Abdominal visceral fat area       0.296                    0.001
  Abdominal subcutaneous fat area   0.009                    0.935
  Thigh subcutaneous fat area       −0.160                   0.060
  HOMA2-IR                          0.091                    0.166

Model adjusted for baseline traits (age, sex, BMI, abdominal visceral fat area, abdominal subcutaneous fat area, thigh subcutaneous fat area, HOMA2-IR) and change in weight.

Data are expressed as standardized *β*.

In addition, when we performed multivariable linear regression analysis of the prediction of change in abdominal visceral fat area and HOMA2-IR over 5 years instead of abdominal visceral fat area and HOMA2-IR at 5 years, we obtained nearly identical results with baseline adiponectin remaining an independent predictor of both outcomes (Supplemental Table 1). As for HOMA2%B, there was no important association between baseline adiponectin and HOMA2%B after adjustment for demographics, overall and regional body composition, and weight change (Supplemental Table 2).

Discussion {#s13}
==========

These prospective data demonstrate that a low baseline adiponectin concentration was related to accumulation of abdominal visceral fat and increases in insulin resistance over 5 years in Japanese Americans. These findings were independent of age, sex, BMI, abdominal visceral fat area, abdominal subcutaneous fat area, thigh subcutaneous fat area, HOMA2-IR at baseline, and weight change. However, baseline adiponectin concentration was not related to future weight, BMI, or other CT-measured regional adipose area in multivariate analyses after adjustment for potential confounding factors. This study demonstrates that baseline adiponectin predicts future change in visceral adiposity directly measured by CT.

Our results were consistent with previous epidemiologic research that reported no association between adiponectin and future body weight and BMI in obese Pima Indians, elderly Caucasians, and overweight Afro-Jamaicans ([@B8]--[@B10]). Weight or BMI is not a direct measurement of body fat and does not capture information on regional body fat distribution. Thus the same weight or BMI may reflect different fat distribution in individuals according to sex, race, and age. In all of the previously mentioned studies, direct repeated measures of regional fat mass were not available. Previous research suggests that the pattern of fat distribution has a greater influence on cardiometabolic risk than fat mass *per se* ([@B25]). In particular, visceral adiposity plays an important role in development of obesity-associated metabolic disorders. Emerging evidence indicates that visceral adiposity measured by CT scan is a more accurate predictor for cardiovascular disease and its risk factors than BMI ([@B26], [@B27]). Furthermore, because at any given BMI Asians have greater visceral adiposity than Caucasians, BMI may be a less accurate anthropometric measure predicting future cardiometabolic risk in this ethnic group ([@B28]).

A prospective study has examined the association between waist circumference and adiponectin concentration, finding that high baseline adiponectin was associated with a lower risk of greater waist circumference as a component of metabolic syndrome in Korean women during 2.6 years of follow-up ([@B29]). Because waist circumference is a crude index of abdominal visceral fat, this result supports our findings; however, this analysis cannot distinguish between whether adiponectin was associated with fat accumulation in the visceral or abdominal subcutaneous fat depot (or both) given that a surface measurement was used and direct imaging was not ([@B30]).

Although we found that adiponectin had an inverse association with abdominal subcutaneous fat area and a positive relationship with thigh subcutaneous fat area in cross-sectional analyses similar to those previously performed, adiponectin was not associated with change in these fat depots in prospective analyses adjusted for confounding factors. Thus, our data do not support an association between adiponectin concentration and change in these fat depots, and, in the case of abdominal subcutaneous fat, suggest potential reverse causation as the underlying association seen in cross-sectional research ([@B14], [@B15]). That is, the inverse relationship between abdominal subcutaneous fat and adiponectin in cross-sectional research can be explained by greater abdominal subcutaneous fat--induced adiponectin suppression.

The biological mechanism linking adiponectin and visceral adipose tissue is not fully understood. Kim *et al.* ([@B18]) reported that a leptin-deficient mouse model with overexpression of adiponectin showed a decrease in visceral fat and increase in subcutaneous fat and improved insulin sensitivity. This finding implies that adiponectin might causally affect body fat distribution.

There are few prospective studies concerning the association between adiponectin and insulin sensitivity. Low baseline adiponectin concentrations were associated with greater insulin resistance over 3 to 4 years in a small sample of Pima Indians ([@B31]) and Native Canadians ([@B32]). In addition, adiponectin concentration was negatively correlated with subsequent change over 2 years in HOMA-IR in middle-aged Japanese men ([@B33]). Because adiposity is known as a key confounder in this relationship, these studies adjusted for percent body fat, waist circumference, or BMI. Our research used directly measured abdominal visceral fat area, abdominal subcutaneous fat area, and thigh subcutaneous fat as covariates in modeling the adiponectin-insulin resistance relationship. We previously demonstrated an association between greater visceral fat area measured by CT and subsequent development of insulin resistance in Japanese Americans ([@B26]). In the current study, low adiponectin significantly predicted insulin resistance independent of BMI, abdominal visceral fat area, abdominal subcutaneous fat area, and thigh subcutaneous fat area. Thus, if causal, the insulin-sensitizing effects of adiponectin may be through pathways other than adiposity. Possible mechanisms for insulin sensitivity may include adiponectin action on skeletal muscle and liver. Previous research showed that adiponectin increased fatty acid oxidation by the activation of 5′-AMP-activated protein kinase in skeletal muscle and liver ([@B7], [@B34], [@B35]). In addition, adiponectin may enhance insulin sensitivity by modulating insulin signaling molecule insulin receptor substrate-2 or by a reduction in ceramides in liver ([@B36], [@B37]).

The strengths of our study include the direct and precise measurement of regional fat compartments using CT scans at two points in time over 5 years, which allowed us to explore the association between the baseline adiponectin and future change in regional body fat distribution beyond what is possible using BMI or surface measurements of adiposity. In addition, the prospective design permits assessment of temporal sequence not possible in cross-sectional research. There are, however, several limitations. Although high-molecular-weight adiponectin is a more physiologically active form, only total adiponectin was measured in this study. But the concentration of high-molecular-weight adiponectin correlates significantly with total adiponectin, and many other studies are also based on the assessment of total adiponectin concentrations, thereby permitting comparison of our results to an established literature ([@B38]). Because we measured adiponectin concentrations at baseline only, we were not able to assess whether changes in adiposity and insulin resistance were associated with longitudinal changes in adiponectin concentration. HOMA-IR is not a gold standard method of assessing insulin resistance. Because HOMA-IR is simply based on basal (*i.e.,* fasting) glucose and insulin concentrations, in contrast to clamps, it does not reflect insulin sensitivity of the stimulated state. Some research has shown that the original HOMA-IR equation compared poorly with directly measured insulin sensitivity derived from the hyperinsulinemic euglycemic clamp or intravenous glucose tolerance test ([@B39], [@B40]). The emerging evidence that race, sex, and insulin secretory function can affect the accuracy of HOMA-IR in estimating insulin sensitivity should also be taken into consideration ([@B40], [@B41]). Despite these limitations, HOMA-IR is still one of the most frequently used tools of determining insulin resistance in large population-based studies. An updated version of HOMA-IR, HOMA2-IR, was developed, and we used the computer model available for its calculation in these analyses ([@B41]). In addition, as is true for all observational research, it is possible that unknown confounding factors may be responsible for the associations noted between adiponectin concentration and adiposity or insulin resistance identified in this study. Finally, this cohort was restricted to Japanese Americans; thus, caution should be taken when generalizing our findings to other populations.

In conclusion, low plasma adiponectin concentration predicted future abdominal visceral fat accumulation and greater insulin resistance in Japanese Americans after adjustment for conventional anthropometric and metabolic variables and direct measurements of regional fat depots. The results suggest that adiponectin may play an important role not only in the regulation of body composition, but also insulin resistance. Further studies are needed to confirm our findings in other populations and enhance understanding of the pathophysiological mechanisms linking adiponectin to accrual of abdominal visceral fat and changes in insulin resistance.

Abbreviations: BMIbody mass indexCTcomputed tomographyHOMA2homeostasis model assessment 2HOMA2%Bhomeostasis model assessment 2 of insulin secretionHOMA2-IRhomeostasis model assessment 2 of insulin resistance.
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